|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| Product Lifecycle Management, 2006 |
|
|
|
|
€ 2 219,00 |
Editeur
: |
Visiongain |
Langue
: |
Anglais |
Date de publication : |
Mai 2006 |
Taille du document : |
152 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (2) |
|
|
|
| 56 pages | Février 2007 | Anglais
|
|
|
| Main
focus: |
pharmaceutical,pharmaceutical industry,...,...
|
| Research
focus: |
pricing policy,market definition, |
| Geographic
focus: |
australia,france,usa,spain,ireland,italy,... |
| |
|
|
|
|
| 158 pages | Juin 2005 | Anglais
|
|
|
| Main
focus: |
pharmaceutical,pharmaceutical industry,...,...
|
| Research
focus: |
industry structure,distribution channels, |
| Geographic
focus: |
usa,france,china,italy,japan,united kingdom,... |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Chinese Markets for Pharmaceuticals 225 pages | Janvier 2002 |
China's demand for pharmaceuticals has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic |
3 500,00 €
|
| |
| |
The Global Parallel Trade Outlook 2001 - 2006: A Country-by-Country Analysis 188 pages | Septembre 2001 |
Global Parallel Trade Outlook 2001: A country-by-country analysis, a new report by Reuters Business Insight, provides a detailed update on the status of parallel trade in the global marketplace.
|
1 200,00 €
|
| |
| |
Antisense Therapy: Technical Aspects and Commercial Opportunities 334 pages | Mars 2000 |
Antisense therapy interferes with the expression of disease-causing proteins, thus offering a direct and selective intervention in the disease process. Besides the well known oligonucleotides ( |
955,00 €
|
| |
| |
Bridging the Pharmaceutical Earnings gap: Key Strategies in the race for growth 173 pages | Mars 2000 |
The favorable climate of the pharmaceutical sector has changed radically over the past ten years. Where once near unrestricted revenue expansion existed, external pressures now act in unison |
955,00 €
|
| |
| |
Regulatory Affairs: Paths to Approval 113 pages | Février 1999 |
Area Specific Chapters : The regulatory systems governing clinical trials and drug approvals are examined for the US, Europe, and Australia, Canada and Japan, including analysis of the implicatio |
795,00 €
|
| |
| |
Patient Power in the Pharmaceutical Industry: The shift towards more informed, more powerful consumers of drugs 119 pages | Juin 1999 |
The dramatic rise in patient power in recent years presents a new and challenging opportunity to pharmaceutical companies, healthcare providers and governments alike. A great need exists for ph |
795,00 €
|
| |
| |
The Drug Discovery Outlook: Drivers of innovation in the 21st Century 189 pages | Octobre 2000 |
The Drug Discovery Outlook: Drivers of innovation in the 21st Century introduces and analyzes the five key enabling technologies and bioinformatics, which are currently driving pharmaceutical dru |
955,00 €
|
| |
| |
Pfizer's Recent Takeover 15 pages | Juillet 2002 |
On 15th July 2002, Pfizer announced the acquisition of Pharmacia in a stock-for-stock transaction valued at $60 billion, expanding the company's core strengths in pharmaceuticals and health care.
|
300,00 €
|
| |
| |
Top Ten and Emerging Pharmaceutical markets 214 pages | Juillet 1999 |
Introduction : Provides the background to the report by identifying the major trends within global healthcare markets and how these interact and influence the markets for pharmaceuticals. Mar |
795,00 €
|
| |
| |
The Pharmaceutical Mergers and Acquisitions Outlook 2001 128 pages | Octobre 2001 |
Pharmaceutical companies have recently undertaken extensive M&A activity to either build critical mass, create organic growth or through strategic alliances to build virtual mass. The Pharmaceu |
1 200,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Product Lifecycle Management, 2006 |
|
|
The global pharmaceutical market with sales of approximately $550 billion is about to enter a pivotal period in its history. The industry has been used to double digit growth rates but growth has now dropped to below 10% for the first time. In addition to this whole swathes of lucrative high revenue earning drugs are going to lose patent. Ordinarily, the industry would have been able to cope with this after all patent loss is a normal part of the industrial process. But this time the industry faces serious problems, pipelines are notoriously thin. The industry is going to have huge difficulties in replacing those drugs going off patent and the high levels of revenue that they earn. The industry is going to have incorporate the new culture of Product Lifecycle Management (PLM) if it is to salvage some of those lost revenues.
Visiongain’s s new report Product Lifecycle Management, 2006 offers an in depth view of this new work strategy. PLM may not be able to save the industry but in times of low growth, patent loss, generic competition and a dearth of new high earning products it is a one of the few viable options. Visiongain’s Product Lifecycle Management, 2006 explains this new method of business and assesses each major aspect of PLM and how they may improve industrial performance. Visiongain’s Product Lifecycle Management, 2006 has to be an essential part of any pharmaceutical company’s outlook.
Why you should buy this report:
The level of imminent patent loss is unprecedented in the history of the pharmaceutical industry Generic companies can expect at least a 50% share of the patent expired market Key product lifecycle management strategies are examined, recent examples considered and the advantages and disadvantages of each assessed Leading drugs in the principal R&D based company pipelines are assessed The key aspects of the patent system are outlined This report considers the latest financial and anecdotal information to enable the most appropriate choice of product lifecycle management strategy to be assessed.
|
|
Product Lifecycle Management, 2006
|
|
|
PPLSEN
|
|
|
|
|